1-20 of 277 Search Results for

BPDCN

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Journal Articles
Journal: Blood
Blood (2013) 122 (21): 3942.
Published: 2013
... Neoplasm (BPDCN), an aggressive malignancy derived from plasmacytoid dendritic cells (PDCs), typically presents as cutaneous lesions, can also involve lymph nodes and spleen, and invariably terminates in an acute leukemic phase. Its diagnosis is based on this clinical presentation, as well as the unique...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal: Blood
Blood (2018) 132 (Supplement 1): 3980.
Published: 2018
..., BA; Lingsha Zhou; Marina Y. Konopleva, MD PhD Background: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare, distinct myeloid malignancy with historically poor survival, a high transformation rate to acute myeloid leukemia (AML), and no standard of care therapeutic approach...
Journal Articles
Journal: Blood
Blood (2018) 132 (Supplement 1): 3899.
Published: 2018
...Hannah Beird, PhD; Maliha Khan; Feng Wang, PhD; Mansour Alfayez, MD; Tianyu Cai, PhD; Li Zhao, PhD; Andy Futreal, PhD; Marina Y. Konopleva, MD PhD; Naveen Pemmaraju, MD Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic neoplasm involving skin lesions...
Journal Articles
Journal: Blood
Blood (2018) 132 (Supplement 1): 2755.
Published: 2018
...Gabriel K Griffin, MD; Katsuhiro Togami, MD PhD; Elizabeth A Morgan, MD; Andrew A. Lane, MD PhD INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic neoplasm with poor outcomes and limited therapeutic options. BPDCN pathogenesis is not clear, given...
Journal Articles
Journal: Blood
Blood (2018) 132 (Supplement 1): 765.
Published: 2018
... Dunn; Peter McDonald; John Mark Sloan, MD; Jeffrey E. Lancet, MD; Hagop M. Kantarjian, MD; Marina Y. Konopleva, MD PhD Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematologic malignancy with a historical overall survival (OS) of ~8-14 months from diagnosis...
Journal Articles
Journal: Blood
Blood (2018) 132 (Supplement 1): 3956.
Published: 2018
... dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy of plasmacytoid dendritic precursor cells. Lacking standard therapy due to limited understanding of biology and historical rarity of the disease, clinical outcomes for BPDCN patients remain poor. Surface overexpression of CD123/IL3Rα...
Journal Articles
Journal: Blood
Blood (2017) 130 (Supplement 1): 1298.
Published: 2017
... to the interleukin-3 receptor α (CD123), a target highly expressed on blastic plasmacytoid dendritic cell neoplasm (BPDCN). SL-401 has been granted breakthrough therapy designation (BTD) for the treatment of patients with BPDCN. BPDCN is an aggressive hematologic malignancy with poor outcomes, including ~12 month...
Journal Articles
Journal: Blood
Blood (2017) 130 (Supplement 1): 3855.
Published: 2017
... Naumovich Konoplev, MD PhD; Keyur P. Patel, MBBS, PhD; Sherry Pierce, BSN, BA; Mark Brandt, BS; Marina Konopleva, MD PhD Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN), now recognized by WHO 2016 as a separate category under myeloid malignancies, is a rare, aggressive disease characterized...
Journal Articles
Journal: Blood
Blood (2017) 130 (Supplement 1): 2625.
Published: 2017
... Pemmaraju, MD; Marina Konopleva, MD PhD Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy. Data on the biology of BPDCN is limited, patient outcomes have historically been poor and there is no established standard of care. Nearly 100% of patients with BPDCN...
Journal Articles
Journal: Blood
Blood (2017) 130 (Supplement 1): 797.
Published: 2017
...+ cancers, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Other than CD123 expression, the determinants of response are largely unknown. Our goal was to study mechanisms of de novo and acquired resistance to inform combination strategies and enhance...
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 4039.
Published: 2016
...Tianyu Cai, PhD; Roman Galetto, PhD; Agnès Gouble, PhD; Julianne Smith, PhD; Antonio Cavazos, MS; Sergej Konoplev, MD PhD; Andrew A. Lane, MD PhD; Monica L. Guzman, PhD; Hagop M. Kantarjian, MD; Naveen Pemmaraju, MD; Marina Konopleva, MD PhD Blastic plasmacytoid dendritic cell neoplasm (BPDCN...
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 4045.
Published: 2016
... Konopleva, MD PhD; Anthony Letai, MD PhD; Andrew A. Lane, MD PhD Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a particularly aggressive hematologic malignancy with median survival of <12 months and no standard therapy. BPDCN involves the skin in nearly all patients, and frequently infiltrates...
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 5183.
Published: 2016
...Gabriela Cesarman-Maus, MD PhD; Carmen Lome, MD; Karla Adriana Espinosa, MD; Carmen Marcela Quezada-Fiallos, MD; Silvia Rivas, MD; Roxana Quezda Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a recently recognized highly aggressive malignant proliferation of plasmacytoid dendritic-cell...
Journal Articles
Journal Articles
Journal: Blood
Blood (2016) 128 (22): 342.
Published: 2016
...; Hagop M. Kantarjian, MD; Marina Konopleva, MD PhD Background: SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed on blastic plasmacytoid dendritic cell neoplasm (BPDCN) and other hematologic malignancies. BPDCN is an aggressive hematologic malignancy...